World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
126
Citations
95133
World Ranking
2872
National Ranking
1597

Overview

Gregory J. Riely is affiliated with Memorial Sloan Kettering Cancer Center in the United States. Their research focuses extensively on oncology, particularly in pulmonary and respiratory medicine, molecular biology, cancer research, and pathology and forensic medicine.

The primary topics of their scientific work include:

  • Lung Cancer Treatments and Mutations
  • Cancer Genomics and Diagnostics
  • Colorectal Cancer Treatments and Studies
  • Lung Cancer Research Studies
  • Lung Cancer Diagnosis and Treatment
  • Cancer Immunotherapy and Biomarkers
  • Radiomics and Machine Learning in Medical Imaging

Gregory J. Riely has co-authored frequently with several scientists, including:

  • Marc Ladanyi (46 publications)
  • Charles M. Rudin (38 publications)
  • Mark G. Kris (38 publications)
  • Helena A. Yu (34 publications)
  • Hira Rizvi (28 publications)

Thevenues where Gregory J. Riely most often publishes are:

  • Journal of Clinical Oncology (43 publications)
  • Journal of Thoracic Oncology (19 publications)
  • Cancer Research (18 publications)
  • Clinical Cancer Research (15 publications)
  • Journal of the National Comprehensive Cancer Network (14 publications)

Significant recent papers authored or co-authored by Gregory J. Riely include:

  • Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology, 2022, Journal of the National Comprehensive Cancer Network
  • NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021, 2021, Journal of the National Comprehensive Cancer Network
  • Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation, 2022, New England Journal of Medicine
  • Analysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal, 2023, Cancer Research
  • Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients, 2022, Cell

The main fields of study associated with their work are medicine, with 390 publications, and biochemistry, genetics and molecular biology, with 130 publications.

Best Publications

  • International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

    William D Travis;Elisabeth Brambilla;Masayuki Noguchi;Andrew G Nicholson

  • Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

    William Pao;Vincent A. Miller;Katerina A Politi;Gregory J. Riely

  • Tumor mutational load predicts survival after immunotherapy across multiple cancer types.

    Robert M Samstein;Chung-Han Lee;Chung-Han Lee;Alexander N Shoushtari;Alexander N Shoushtari;Matthew D Hellmann;Matthew D Hellmann

  • Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

    Alice T. Shaw;Dong Wan Kim;Kazuhiko Nakagawa;Takashi Seto

  • Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

    Ahmet Zehir;Ryma Benayed;Ronak H Shah;Aijazuddin Syed

  • Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

    Helena A. Yu;Maria E. Arcila;Natasha Rekhtman;Camelia S. Sima

  • OncoKB: A Precision Oncology Knowledge Base.

    Debyani Chakravarty;Jianjiong Gao;Sarah Phillips;Ritika Kundra

  • Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

    Alice T. Shaw;Sai Hong I. Ou;Yung Jue Bang;D. Ross Camidge

  • MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

    James Bean;Cameron Brennan;Jin-Yuan Shih;Gregory Riely

  • KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

    William Pao;Theresa Y Wang;Gregory J Riely;Vincent A Miller

  • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

    Nicole M. Kuderer;Toni K. Choueiri;Dimpy P. Shah;Yu Shyr

  • Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer

    Alice T. Shaw;Dong Wan Kim;Ranee Mehra;Daniel S W Tan

  • Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

    D. Ross Camidge;Yung Jue Bang;Eunice L. Kwak;A. John Iafrate

  • Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.

    Hira Rizvi;Francisco Sanchez-Vega;Konnor La;Walid Chatila

  • Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology

    David S. Ettinger;Douglas E. Wood;Dara L. Aisner;Wallace Akerley

  • Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

    Alice T. Shaw;Beow Y. Yeap;Benjamin J. Solomon;Gregory J. Riely

  • Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases

    Akihiko Yoshizawa;Noriko Motoi;Noriko Motoi;Gregory J Riely;Cami S Sima

  • Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors

    Marissa N. Balak;Yixuan Gong;Gregory J. Riely;Romel Somwar

  • Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

    David Jackman;William Pao;Gregory J. Riely;Jeffrey A. Engelman

  • Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.

    Kathryn C Arbour;Gregory J Riely

Frequent Co-Authors

Mark G. Kris
Mark G. Kris Memorial Sloan Kettering Cancer Center
Marc Ladanyi
Marc Ladanyi Memorial Sloan Kettering Cancer Center
Maria E. Arcila
Maria E. Arcila Memorial Sloan Kettering Cancer Center
Charles M. Rudin
Charles M. Rudin Memorial Sloan Kettering Cancer Center
Matthew D. Hellmann
Matthew D. Hellmann Memorial Sloan Kettering Cancer Center
William Pao
William Pao Roche (United States)
Alexander Drilon
Alexander Drilon Memorial Sloan Kettering Cancer Center
Alice T. Shaw
Alice T. Shaw Harvard University
Valerie W. Rusch
Valerie W. Rusch Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in healthcare but not ready to commit to medical school, many flexible online programs can help you start your career quickly. For those seeking advanced practice roles, cheapest direct entry msn programs offer a cost-effective route for non-nurses aiming to become nurse practitioners or leaders in the field.

Alternatively, online adn programs for non nurses can be a smart choice for those wanting to enter registered nursing through associate degrees without prior nursing experience. If patient care isn’t your goal, administrative careers like medical billing and coding also remain in high demand. Explore the best medical billing and coding schools online that provide accredited, flexible schooling with financial aid options.

Finally, those concerned about entrance exams will find that some nursing school that don't require teas or HESI exams can offer a more accessible admission process. With these online pathways, gaining entry into the healthcare profession has never been more accessible or affordable.

Best Scientists Citing Gregory J. Riely

Trending Scientists